Psychoactive Substances Bill [HL]

Insert the following new Clause—

“Republic of Ireland: impact assessment

(1)     The Secretary of State must conduct an impact assessment of the Republic
of Ireland’s Criminal Justice (Psychoactive Substances) Act 2010.

(2)     The Secretary of State must publish a report setting out whether or not the
impact assessment under subsection (1) justifies the commencement of this
Act in its current form.”

Insert the following new Clause—

“Monitoring

Following the commencement of this Act, the Secretary of State must
publish a report annually setting out the impact of this Act, including on
deaths and other harms caused by all controlled and banned substances.”

Page 2, line 10, at end insert—

“(2A)    The Secretary of State must add a substance to Schedule 1 under subsection
(2)(a) if it is deemed to pose low health, social and safety risks.

(2B)    A substance is deemed to pose low health, social and safety risks under
subsection (2A) if it is so determined by an independent committee
comprising experts nominated by the Royal College of Psychiatrists, the
British Pharmacological Society and the Academy of Medical Sciences.”

Page 3, line 11, at end insert—

“( )     For the purposes of this section, patrons of entertainment establishments
and those responsible for health and social care services and prisons are

exempt from liability for their clients’ use of psychoactive substances on
their premises within the meaning of this Act.”

Page 33, line 7, leave out subsection (1) and insert—

“(1)     This section comes into force on the day on which this Act is passed.”

Page 33, line 12, at end insert—

“( )     The Secretary of State may not make regulations under subsection (2) until
she has published a report under section (Republic of Ireland: impact
assessment).”

Page 34, line 7, leave out paragraph 2 and insert—

“2     All medicinal products prescribed by a doctor or sold by a licensed
pharmacist.”

Page 34, line 13, leave out paragraph 3 and insert—

“3     All research pharmaceuticals being used to develop new medicines or
progress neuroscience research.”

Page 34, line 16, at end insert—

“      Low non-psychoactive doses of psychoactive substances.”